Pulmatrix (NASDAQ:PULM – Get Free Report) released its quarterly earnings data on Friday. The biotechnology company reported ($0.54) EPS for the quarter, Zacks reports. Pulmatrix had a negative net margin of 96.51% and a negative return on equity of 45.97%.
Pulmatrix Price Performance
Shares of NASDAQ PULM traded down $0.21 during midday trading on Friday, reaching $7.40. 1,748 shares of the stock traded hands, compared to its average volume of 131,939. The company’s 50 day moving average is $7.44 and its 200 day moving average is $5.13. Pulmatrix has a one year low of $1.56 and a one year high of $10.40. The stock has a market capitalization of $26.99 million, a PE ratio of -2.80 and a beta of 1.66.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on Pulmatrix in a research report on Sunday, January 5th. They issued a “hold” rating on the stock.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- Expert Stock Trading Psychology Tips
- FedEx Delivers Another Crushing Blow to Its Stock Price
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- Growth Stocks: What They Are, Examples and How to Invest
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
